Biotechnology

Enliven Therapeutics Stock (ELVN): Promising Advances in Oncology Pipeline

Enliven Therapeutics continues to progress in its oncology trials with key Phase 1 data readouts expected in 2025 and a strong cash runway into 2027—discover the latest updates now.

Mineralys Therapeutics Stock (MLYS): Strategic Offering to Fuel Growth

Mineralys Therapeutics has priced a public offering to raise $175 million to advance clinical development of innovative treatments.

Roche Stock (OTC: RHHBY): Strategic Collaboration for Obesity Treatment

Roche partners with Zealand Pharma to co-develop petrelintide, targeting the growing obesity market with promising therapeutic solutions.

Takeda Pharmaceutical Stock (NYSE: TAK): Strategic Focus on Oncology and Growth Opportunities

Takeda's revamped oncology strategy prioritizes key tumors and innovative partnerships, enhancing growth prospects and market positioning.

2Seventy Bio (TSVT): Surge Following Acquisition Announcement

2Seventy Bio jumps 77% as Bristol Myers Squibb announces a $5-per-share buyout. Learn how this deal reshapes biotech investing and what it means for you.

Interim Data Update from Medicus Pharma’s Phase 2 Clinical Trial

Medicus Pharma reports a positive trend in its interim Phase 2 trial analysis for a revolutionary skin cancer treatment. Key details on this major breakthrough.

FAQs on Medicus Pharma's Interim Data Update - 6 March 2025

Medicus Pharma reports a positive trend in its interim Phase 2 trial analysis for a novel skin cancer treatment. Here are FAQs explaining this breakthrough.

High Demand, Few Options: The Skin Cancer Treatment Gap

Basal Cell Carcinoma is 7x more common than melanoma, yet patients remain underserved. Sun and fair skin fuel its rise. Explore a rising need for treatments.

Illumina Inc. (ILMN): Navigating Trade Restrictions Amid Rising Competition

China's ban on Illumina’s gene-sequencing machines escalates trade tensions, opening market share to domestic rivals. Investors should watch for biotech volatility.

Moderna Faces Challenges, MRNA Stock Continues YTD Decline

Moderna faces challenges with declining sales and pipeline delays, raising concerns for investors as it navigates its 2025 outlook in a shifting market.

Shares Soar as GH Research Unveils Promising Drug Trial

GH Research PLC's stock soared 89% after promising results for GH001, an innovative therapy for treatment-resistant depression. Explore the potential.

Thermo Fisher Posts Strong Q4 Earnings Boosting Stock

Thermo Fisher Scientific's Q4 results show increased earnings and revenue, with strong product launches and a positive outlook for future growth.

Akero (AKRO) Stock Surges on Promising Drug Results

Akero Therapeutics' efruxifermin shows promising results in treating liver cirrhosis, driving stock surges and revealing new investment prospects in biotech.

J&J Achieves Strong Q4 Performance

Johnson & Johnson's Q4 results reveal strong revenue growth, driven by Darzalex sales, and an optimistic outlook for 2025 amidst strategic acquisitions.

Intuitive Surgical Surpasses Q4 Expectations

Intuitive Surgical's Q4 revenue surged 25%, fueled by strong system placements. Analysts express optimism about future growth.